PMID- 28721931
OWN - NLM
STAT- MEDLINE
DCOM- 20180827
LR  - 20180827
IS  - 1952-4013 (Electronic)
IS  - 1167-1122 (Linking)
VI  - 27
IP  - 6
DP  - 2017 Dec 1
TI  - TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin 
      lesions and anti-Sm antibody.
PG  - 646-647
LID - 10.1684/ejd.2017.3101 [doi]
FAU - Miyagawa, Fumi
AU  - Miyagawa F
AD  - Department of Dermatology.
FAU - Sugano, Yuka
AU  - Sugano Y
AD  - Department of Dermatology.
FAU - Sho, Masayuki
AU  - Sho M
AD  - Department of Surgery, Nara Medical University School of Medicine, 840 Shijo,
      Kashihara, Nara 634-8522, Japan.
FAU - Asada, Hideo
AU  - Asada H
AD  - Department of Dermatology.
LA  - eng
PT  - Case Reports
PT  - Letter
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (Pyridines)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - B76N6SBZ8R (gemcitabine)
RN  - U3P01618RT (Fluorouracil)
RN  - UA8SE1325T (gimeracil)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse
      effects
MH  - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Drug Therapy, Combination/adverse effects
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis
MH  - Lupus Erythematosus, Systemic/*chemically induced/diagnosis
MH  - Male
MH  - Oxonic Acid/adverse effects
MH  - Pancreatic Neoplasms/drug therapy
MH  - Pyridines/adverse effects
MH  - Renal Insufficiency/chemically induced
MH  - Tegafur/adverse effects
EDAT- 2017/07/20 06:00
MHDA- 2018/08/28 06:00
CRDT- 2017/07/20 06:00
PHST- 2017/07/20 06:00 [pubmed]
PHST- 2018/08/28 06:00 [medline]
PHST- 2017/07/20 06:00 [entrez]
AID - ejd.2017.3101 [pii]
AID - 10.1684/ejd.2017.3101 [doi]
PST - ppublish
SO  - Eur J Dermatol. 2017 Dec 1;27(6):646-647. doi: 10.1684/ejd.2017.3101.